Andrew S. Brohl - Concepedia

Author

Andrew S. Brohl

Also Known As

A Bröhl, A. Brohl, A. Bröhl, A.S. Brohl, Andreas Bröhl, Andrew S. Brohl, Andrew Brohl, Andrew S Brohl, Andrew S. Brohl, Andrew Scott Brohl

300

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

Moffitt Cancer Center National Cancer Institute Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute University of Washington

About

Andrew S. Brohl is an author at Moffitt Cancer Center specializing in medicine, pathology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	22	1.8K
2	Cell Biology	8	8	252
3	Health Sciences	6	6	293
4	Engineering	3	3	533
5	Public Health	1	1	210

Andrew S. Brohl

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors Jack F. Shern, Li Chen, Juliann Chmielecki, Cancer Discovery	2014	759
The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation Andrew S. Brohl, David A. Solomon, Wendy Chang, PLoS Genetics Ewing SarcomaEngineeringSomatic VariantMalignant DiseaseTumor Heterogeneity	2014	440
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy Paul Nghiem, Shailender Bhatia, Evan J. Lipson, Journal of Clinical Oncology	2019	386
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma Megan H. Pollack, Helen Clare Dearden, K. Rapazzo, Annals of Oncology Cancer ImmunosurveillanceOncologyMelanomaImmunologyTumor Immunity	2017	381
Monogenic and polygenic determinants of sarcoma risk: an international genetic study Mandy L. Ballinger, David L. Goode, Isabelle Ray‐Coquard, The Lancet Oncology EpidemiologySarcoma RiskPolygenic RiskGenetic EpidemiologyImmunology	2016	210
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial Sandra P. D’Angelo, Shailender Bhatia, Andrew S. Brohl, Journal for ImmunoTherapy of Cancer	2020	193
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy Todd C. Knepper, Meagan Montesion, Jeffery S. Russell, Clinical Cancer Research	2019	162
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma Paul Nghiem, Shailender Bhatia, Evan J. Lipson, Journal for ImmunoTherapy of Cancer	2021	137
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study Sandra P. D’Angelo, Célèste Lebbé, Laurent Mortier, Journal for ImmunoTherapy of Cancer	2021	137
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial Sungjune Kim, Evan Wuthrick, Dukagjin Blakaj, The Lancet Open LabelRadiation TherapyMedicineCancer TreatmentPhase 2	2022	126

Page 1